Dr. Jordi Monés addresses the TREND Study Investigator Meeting in Budapest
The Novartis pharmaceutical company organised the TREND Study Investigator Meeting in Budapest last Friday, 31 January. The event enabled doctors, medical specialists and international researchers to display their experience and work on clinical practice.
The speakers included Dr. Jordi Monés, the Director of the Institut de la Màcula and an ophthalmologist who specialises in the macula, retina and vitreous. In an address entitled “Clinical Background and Rationale of Treat and Extend Dosing Regimen”, Dr. Monés contributed his knowledge and his experience in the use of the proactive treatment of AMD in comparing it with the monthly system.
Under this protocol, it is recommended to see a specialist on noting the first symptoms of the eye condition. A series of tests will then be carried out to check the veracity of the symptoms. On confirmation, the patient must undergo a specialised, individualised treatment in an attempt to halt the disease. The treatment is usually proactive and anticipatory where it is the physician rather than the disease taking the initiative.
The aim of the TREND Study is to demonstrate that the “Treat & Extend” protocol on which the Fusion® Protocol is based and which is performed at our centre is as effective as the monthly protocol (which is not applicable in most cases due to its greater cost and impracticability with respect to “Treat & Extend”).
Dr. Hussein Muhtaseb, the Institut’s specialist retinal ophthalmologist, also attended the Meeting as a co-investigator of this new study by Novartis